Uniqure NV
NASDAQ:QURE
Uniqure NV
NASDAQ:QURE
Price:
4.69 USD
0.21%
Market Closed
Updated:
May 5, 2024
Section:
Relative Value
The Relative Value of one
QURE
stock under the Base Case scenario is
14.27
USD.
Compared to the current market price of 4.69 USD,
Uniqure NV
is
Undervalued by 67%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
QURE
Relative Value
Base Case
14.27
USD
Undervaluation 67%
Valuation Multiples
Multiples Across Competitors
QURE Competitors Multiples
Uniqure NV Competitors
Uniqure NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
|
Uniqure NV
NASDAQ:QURE
|
224.3m USD | 14.2 | -0.7 | -0.4 | -0.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 5.3 | 60 | 13 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 5.9 | 24.8 | 17.9 | 26.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 8 | 26.5 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.9 | 166.8 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 7 | -10.1 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 3.3 | 27.1 | 13.9 | 17.4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
